Healthcare Expertise
Researchers with pharma and healthcare backgrounds who understand clinical, regulatory, and commercial language.
Research Solutions
Market Access Research in Poland
Reimbursement intelligence, payer research, and KOL insights for pharma and medtech market entry
Beyond Approval — The Access Challenge
Getting a product approved is one challenge. Getting it reimbursed, prescribed, and used — that’s market access. In Poland’s complex healthcare system, market access research provides the intelligence pharma, biotech, and medtech companies need to navigate reimbursement processes, understand payer decision-making, map prescriber behaviours, and build evidence that supports formulary inclusion and pricing negotiations.
Poland’s Reimbursement System
Poland’s reimbursement landscape. The Polish reimbursement system is managed by the Ministry of Health with input from AOTMiT (the Agency for Health Technology Assessment and Tariff System). Our market access research maps the current reimbursement status of your therapeutic area, identifies upcoming decisions and policy changes, assesses competitor positioning, and evaluates the evidence requirements for successful reimbursement applications.
KOL & Payer Intelligence
KOL and payer research. We conduct expert interviews with Key Opinion Leaders (medical specialists, clinical trial investigators, HTA assessors), payers (NFZ regional directors, hospital pharmacy directors), and policy influencers (Ministry of Health advisors, patient organisation leaders). These interviews reveal prescribing motivations, formulary decision criteria, budget impact concerns, and competitive perceptions.
Evidence Generation for HTA
Evidence generation support. We support HTA evidence packages with: patient-reported outcome (PRO) studies, treatment pathway mapping, real-world evidence (RWE) surveys, cost-effectiveness data collection, and burden of disease quantification. Our research generates the primary data that strengthens reimbursement dossiers.
Medtech, Diagnostics & Digital Health
Beyond pharma. We apply market access methodology to medtech, diagnostics, and digital health products navigating Polish healthcare procurement, hospital purchasing, and public tender processes.
Market in Numbers
AOTMiT
Poland’s HTA agency
KOL + payer
dual-stakeholder research
RWE
real-world evidence generation
HTA support
evidence for reimbursement dossiers
Sources: AOTMiT, NFZ, Fieldstat pharma practice
Market Access Research Components
| Component | Method | Stakeholders | Output |
|---|---|---|---|
Reimbursement landscape |
Desk research + expert interviews |
HTA assessors, policy experts |
Reimbursement pathway map |
KOL research |
In-depth interviews |
Medical specialists, investigators |
Prescribing drivers, unmet needs |
Payer research |
Expert interviews |
NFZ, hospital pharmacies |
Formulary criteria, budget concerns |
Patient outcomes |
CAWI/CATI surveys |
Patients, caregivers |
PRO data, burden of disease |
Competitor assessment |
Desk + primary |
All stakeholders |
Competitive positioning map |
Sample Research Questions
What regulatory barriers hinder entry into the Polish market?
What does the drug reimbursement process look like and what data supports it?
Who are the key decision-makers in the public sector procurement process?
What economic arguments support including the product in the basket?
How to effectively position an innovative product in a regulated market?
Why Fieldstat?
KOL Network
Access to Key Opinion Leaders, HTA assessors, and payer decision-makers across Poland.
HTA Evidence Support
We generate primary data for reimbursement dossiers: PRO studies, RWE, burden of disease.
Benefits
- Reimbursement pathway mapping for Poland’s healthcare system
- KOL interview insights on prescribing and treatment decisions
- Payer research revealing formulary criteria and budget concerns
- Patient-reported outcome (PRO) study design and execution
- Real-world evidence (RWE) data collection
- Competitor reimbursement and market positioning analysis
- HTA evidence package support
- Regulatory and policy monitoring
Applications
Pharma product launch market access strategy
Reimbursement dossier evidence generation
KOL mapping and engagement strategy
Payer value proposition development
Treatment pathway and patient journey mapping
Medtech and diagnostics market entry
Hospital procurement and tender intelligence
Implementation Process
1
Access Strategy Brief
We define the therapeutic area, access challenge, stakeholders to engage, and evidence needs.
2
Landscape Assessment
We map the reimbursement landscape, competitor positions, and regulatory environment.
3
Stakeholder Research
We conduct KOL interviews, payer interviews, and/or patient surveys to fill intelligence gaps.
4
Evidence Generation
We design and execute PRO studies, RWE surveys, or burden-of-disease research as needed.
5
Market Access Report
Comprehensive market access strategy with stakeholder insights, evidence summary, and recommended positioning.
Frequently Asked Questions
What is AOTMiT?
The Agency for Health Technology Assessment and Tariff System — Poland’s HTA body that evaluates clinical and cost-effectiveness of healthcare interventions.
How much does market access research cost?
Landscape assessments from PLN 15,000. Full market access studies with KOL + payer interviews from PLN 40,000.
Do you cover medtech and diagnostics?
Yes. We apply market access methodology to medical devices, diagnostics, and digital health products.
What is market access research?
Market access research helps pharmaceutical and medtech companies navigate reimbursement, pricing, and formulary decisions. It provides evidence for Health Technology Assessment (HTA) submissions and payer negotiations.
What is AOTMiT and why does it matter?
AOTMiT is Poland’s Agency for Health Technology Assessment. Its recommendations determine whether a drug or device gets public reimbursement — critical for commercial success in the Polish market.
What types of stakeholders are interviewed?
Key Opinion Leaders (KOLs), HTA assessors, NFZ (National Health Fund) representatives, hospital pharmacists, and patient advocacy organisations.
Industry Sources & Standards
External sources and industry organizations related to this research method:
Related Sectors
This solution is most frequently applied in the following industries: